fig2

Figure 2. (A) Heatmap of metabolic pathways identified to have a LDA > 2.0 using LEfSe analysis for the clinical feature: time to PFS. Unstratified abundances of all pathways produced by Humann3 were run through LEfSe. Pathways identified as a discriminative feature as a LDA > 2.0 was then selected to create the heatmap. We categorized PFS into two groups: > 6 months and ≤ 6 months; (B) Antibiotic resistance genes identified in CALADRIO samples using Resfinder associated with CB. LDA: Linear discriminant analysis; LEfSe: linear discriminant analysis effect size; PFS: progression-free survival; CB: clinical benefit.